enzastaurin has been researched along with bortezomib in 8 studies
| Studies (enzastaurin) | Trials (enzastaurin) | Recent Studies (post-2010) (enzastaurin) | Studies (bortezomib) | Trials (bortezomib) | Recent Studies (post-2010) (bortezomib) |
|---|---|---|---|---|---|
| 188 | 52 | 99 | 6,868 | 860 | 4,753 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 7 (87.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Barrientos, J; Elstrom, R; Leonard, JP; Martin, P | 1 |
| Dreyling, M; Hartmann, E; Hutter, G; Rosenwald, A; Weinkauf, M; Zimmermann, Y | 1 |
| Abonour, R; Anderson, KC; Desaiah, D; Ghobrial, IM; Harris, BN; Laubach, JP; Munshi, NC; Myrand, SP; Porter, NM; Richardson, PG; Schlossman, RL; Shi, P; Wooldridge, JE | 1 |
| Ghobrial, IM; Roccaro, AM; Sacco, A | 1 |
| Ogura, M | 1 |
| Chang, H; Chen, GA; Chen, J; Chen, Y; Evans, K; Qiu, L; Reece, D; Saha, MN; Yang, Y | 1 |
| Bari, A; Civallero, M; Cosenza, M; Marcheselli, L; Pozzi, S; Sacchi, S | 1 |
2 review(s) available for enzastaurin and bortezomib
| Article | Year |
|---|---|
Targeted treatment and new agents in diffuse large B-cell lymphoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Drug Delivery Systems; Humans; Hydroxamic Acids; Immunologic Factors; Indoles; Inhibitor of Apoptosis Proteins; Lymphoma, Large B-Cell, Diffuse; Microtubule-Associated Proteins; Neoplasm Proteins; Protease Inhibitors; Protein Kinases; Pyrazines; Survivin; TOR Serine-Threonine Kinases; Treatment Outcome; Vorinostat | 2008 |
Anti-angiogenic therapies in the treatment of Waldenstrom's Macroglobulinemia.
Topics: Angiogenesis Inhibitors; Bone Marrow; Boronic Acids; Bortezomib; Endothelial Cells; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Panobinostat; Protease Inhibitors; Proteasome Inhibitors; Protein Kinase C; Pyrazines; TOR Serine-Threonine Kinases; Tumor Microenvironment; Waldenstrom Macroglobulinemia | 2011 |
2 trial(s) available for enzastaurin and bortezomib
| Article | Year |
|---|---|
A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Female; Humans; Indoles; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Time Factors | 2011 |
[Current development of new drugs in malignant lymphoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Brentuximab Vedotin; Diphtheria Toxin; Drug Discovery; Everolimus; Humans; Hydroxamic Acids; Immunoconjugates; Indoles; Inotuzumab Ozogamicin; Interleukin-2; Lenalidomide; Lymphoma; Lymphoma, B-Cell; Nitrogen Mustard Compounds; Purine Nucleosides; Pyrazines; Pyrimidinones; Recombinant Fusion Proteins; Sirolimus; Thalidomide; Vorinostat | 2012 |
4 other study(ies) available for enzastaurin and bortezomib
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Combined RNA-expression and 2D-PAGE-screening identifies comprehensive interaction networks affected after bortezomib or enzastaurin exposure of mantle cell lymphoma.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Electrophoresis, Gel, Two-Dimensional; Gene Expression Profiling; High-Throughput Screening Assays; Humans; Indoles; Lymphoma, Mantle-Cell; Prognosis; Protease Inhibitors; Protein Kinase C; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Recurrence | 2010 |
Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cyclin E; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p27; Disease Models, Animal; Drug Resistance, Neoplasm; E2F1 Transcription Factor; Gene Expression Regulation, Neoplastic; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Membrane Proteins; Mice; Multiple Myeloma; Myristoylated Alanine-Rich C Kinase Substrate; Neoplasm Transplantation; Phosphorylation; Primary Cell Culture; Pyrazines; RNA, Small Interfering; S-Phase Kinase-Associated Proteins; Signal Transduction; Survival Analysis | 2015 |
The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines.
Topics: Antineoplastic Agents; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Female; Humans; Indoles; Lenalidomide; Lymphoma, Mantle-Cell; Male; Signal Transduction; Thalidomide | 2015 |